---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-26-000006"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T05:11:40.172524+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific reports Q4 and full year 2025 results, announces acquisitions

## Summary
- Q4 2025 net sales $5.286B, up 15.9% reported; GAAP EPS $0.45, adjusted EPS $0.80.
- FY2025 net sales $20.074B, up 19.9%; GAAP net income $2.898B, adjusted EPS $3.06.
- Agreed to acquire Penumbra (PEN), a thrombectomy and neurovascular company.
- Agreed to acquire Valencia Technologies for its eCoin tibial nerve stimulation device.
- Completed acquisition of Nalu Medical for peripheral nerve stimulation system.

## SEC filing metadata
- accession: 0000885725-26-000006
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572526000006/0000885725-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572526000006/bsx-20260204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-26-000006
- JSON: https://secwatch.observer/filing/0000885725-26-000006.json
- Plain text: https://secwatch.observer/filing/0000885725-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.